Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ARDX
ARDELYX, INC.
NASDAQ
$3.78
▲ UP 1.89% (0.07)

KEY STATISTICS

Market Cap$933.77 M
52w High$8.40
52w Low$3.68
Dividend Yield—
Frequency—
P/E-17.66
Volume2.98M
Shares Out.247.03M

COMPANY

LEADERSHIP

Michael G. Raab
CHIEF EXECUTIVE
Michael G. Raab

COMPENSATION 2026

Salary$797,000
Stock Awards$2,953,724
Incentive Plan Pay$627,638
All Other Comp.$3,861
Total$7,796,171

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 19, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
489

PRICE TARGET

Target High$17.00
Target Low$13.00
Target Median$15.00
Target Consensus$15.00

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$129.22M
OCT
29
THU

SPLIT RECORD

DATETYPERATIO
2021-07-20Forward4:1

PRICE

$3.78 ▲ UP 1.89% (+$0.07)
OVERLAYS
$3.69$3.72$3.75$3.789:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM3.78

About Ardelyx, Inc.

https://www.ardelyx.com ↗

Ardelyx, Inc. is a biopharmaceutical company developing gastrointestinal and cardiorenal medicines, including tenapanor for IBS-C and hyperphosphatemia, with global partnerships and a focus on innovative therapies.

INDUSTRY

Biotechnology

A PRODUCT ARDELYX, INC. IS KNOWN FOR

XPHOZAH (tenapanor)
XPHOZAH (tenapanor)

Ardelyx's first-in-class phosphate absorption inhibitor, approved in late 2023, reduces serum phosphorus in adults with chronic kidney disease on dialysis, serving as a key growth driver addressing a critical unmet need.

COMPETITORS

COMPETITOR
AKBA COMPARE
AMGN COMPARE
FMS COMPARE
PFE COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$105.52M — $93.37M ▼$118.13M ▲
Product IBSRELA$78.16M — $70.07M ▼$86.24M ▲
License$25K $243M ▲$51K ▼$96K ▲

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
UNITED STATES$15.6M $83.28M ▲$319.2M ▲$377.81M ▲
Asia Pacific$36.53M $41.12M ▲$78K ▼$29.17M ▲
North America— $59K $14.34M ▲$342K ▼
CANADA$31K — — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
125
LISTED HERE
25
RANKED BY POSITION SIZE
XBI
0.26% · 7.9M
VTS.AX
0.00% · 7.4M
IWM
0.03% · 6.3M
PBE
2.67% · 3.1M
SCHA
0.02% · 1.2M
FYC
0.20% · 751.1K
LABU
0.17% · 263.9K
BBP
0.80% · 257.3K
XRSG.L
0.03% · 218.1K
ISMD
0.15% · 135.2K
RSSL
0.03% · 117.2K
FHLC
0.01% · 109.9K
BBSC
0.03% · 66.2K
FSML
0.05% · 19.9K
TILT
0.00% · 17.2K
RTWO.L
0.02% · 14.4K
ESSC
0.12% · 11.7K
URTY
0.01% · 9.6K
VETS
0.15% · 6.2K
TMFX
0.05% · 4.5K
SXQG
0.02% · 3.2K
AVTM
0.00% · 1.4K
USFMDN.MX
0.00% · 1.1K
RESM
0.03% · 461
SYZ
0.00% · 88

INSTITUTIONAL OWNERSHIP

SHARES OWNED
65.90%
HOLDERS
341
TOP 12 OF 341 · RANKED BY POSITION SIZE
Blackrock, Inc.
23.5M sh · $119.87M
Vanguard Group Inc
19.0M sh · $110.65M
Millennium Management LLC
17.8M sh · $106.88M
Blackrock Inc.
17.6M sh · $130.06M
Rubric Capital Management LP
16.2M sh · $82.63M
Janus Henderson Group Plc
14.5M sh · $84.58M
State Street Corp
13.6M sh · $81.49M
Macquarie Group Ltd
10.5M sh · $57.61M
Macquarie Management Holdings, Inc.
9.5M sh · $48.69M
Marshall Wace, Llp
8.9M sh · $49.28M
Geode Capital Management, LLC
6.4M sh · $32.66M
Nuveen, LLC
5.2M sh · $31.36M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Hohenleitner Susan
Sale · 1.6K shares
2026-08-21
★
OFFICER: SEE REMARKS
Bishop John E
Sale · 17.3K shares
2026-08-21
★
OFFICER: CHIEF HUMAN RESOURCES OFFICER
Brady James Parker
Sale · 13.2K shares
2026-08-21
★
OFFICER: CHIEF BUSINESS OFFICER
Kelliher Mike
Sale · 3.1K shares
2026-08-21

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OUTPERFORM 1
OVERWEIGHT 1
6 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM Piper Sandler OVERWEIGHT Citigroup BUY BTIG BUY TD Cowen BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
SYRE$88.98COMPARE
BCRX$9.96COMPARE
PHVS$35.25COMPARE
TRVI$17.26COMPARE
ZYME$29.19COMPARE
STOK$29.81COMPARE
NTLA$12.74COMPARE
MAZE$26.21COMPARE